| P50 | author | Mohammad Reza Safarinejad | Q42714066 |
| P2860 | cites work | Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease | Q28215274 |
| | Dietary polyunsaturated fatty acids and inflammatory mediator production | Q33807447 |
| | Procarbazine (Natulan) in the treatment of Peyronie's disease | Q34057899 |
| | Omega-3 fatty acids in inflammation and autoimmune diseases | Q34164525 |
| | The natural history of Peyronie's disease | Q34253179 |
| | Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study | Q34403964 |
| | Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study | Q34429388 |
| | A critical analysis of nonsurgical treatment of Peyronie's disease | Q34525595 |
| | n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases | Q34569101 |
| | Pathophysiology of Peyronie's disease | Q35010236 |
| | Peyronie's disease: a review | Q35082687 |
| | Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis | Q35150616 |
| | Colour Doppler ultrasound of the penis. | Q35166471 |
| | Expanding the paradigm for plaque development in Peyronie's disease | Q35556736 |
| | Diet and rheumatoid arthritis: a review of the literature | Q36272337 |
| | Peyronie's disease: etiology, epidemiology and medical treatment | Q36314058 |
| | Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids | Q36571147 |
| | Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. | Q36579978 |
| | Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease | Q36648279 |
| | Peyronie's disease (CME). | Q36986101 |
| | Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies | Q37013837 |
| | Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire | Q43597832 |
| | A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms | Q43832862 |
| | A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs | Q44169143 |
| | Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes | Q44179201 |
| | The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study | Q44934972 |
| | Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study | Q46242804 |
| | Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia | Q49067556 |
| | Dietary supplementation with marine fish oil improves in vitro small artery endothelial function in hypercholesterolemic patients: a double-blind placebo-controlled study. | Q50921032 |
| | The chronology of depression and distress in men with Peyronie's disease. | Q51889728 |
| | Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. | Q53230701 |
| | The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. | Q53963640 |
| | Vascular abnormalities in Peyronie's disease: the role of color Doppler sonography. | Q54214710 |
| | Tamoxifen versus placebo in the treatment of Peyronie's disease. | Q55033437 |
| | Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report | Q63694274 |
| | Classification of congenital and acquired penile deviation | Q71812770 |
| | Plasma fatty acid composition as an indicator of habitual dietary fat intake in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study Investigators | Q72026146 |
| | Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial | Q72991357 |
| | Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction | Q73359029 |
| | Electron microscopic study of the penile plaques and adjacent corpora cavernosa in Peyronie's disease | Q73584002 |
| | Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study | Q76372661 |
| | The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease | Q77974651 |
| | Primary prevention of cardiovascular disease: a call to action | Q78674148 |
| | Seeking answers on the quest for effective nonsurgical treatment of Peyronie's disease | Q79329764 |
| | Intralesional verapamil prevents the progression of Peyronie's disease | Q80485567 |
| | The natural history of Peyronie's disease: an ultrasonography-based study | Q80730636 |
| | Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls | Q81480502 |
| | An analysis of the natural history of Peyronie's disease | Q83335142 |
| P433 | issue | 6 | |
| P921 | main subject | placebo | Q269829 |
| | Peyronie's disease | Q874586 |
| P1104 | number of pages | 12 | |
| P304 | page(s) | 1743-1754 | |
| P577 | publication date | 2009-04-23 | |
| P1433 | published in | The Journal of Sexual Medicine | Q7743627 |
| P1476 | title | Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: A prospective, randomized, double-blind placebo-controlled study. | |
| P478 | volume | 6 | |